According to published results, a novel opioid-free pathway may provide noninferior pain management compared with an opioid-containing pathway during the perioperative period in patients undergoing ...

Dysmenorrhea Treatment Market size is expected to be worth around USD 10.1 Bn by 2032 from USD 4.7 Bn in 2023, growing at a CAGR of 8.2% ...

Patients who experience musculoskeletal pain have many pharmaceutical options for relief — unless they also suffer from ...

Fibromyalgia is a complex, chronic disorder characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, ...

The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but ...

The Food and Drug Administration has approved a first-of-its-kind non-opioid pain medication, providing a new option for ...

Recent developments, however, suggest that strategies to treat pain are starting to match its complexity with a new ...

A new study has found that adults with newly diagnosed sciatica who received chiropractic spinal manipulation (CSM) were significantly less likely to experience opioid-related adverse drug events ...

The Food and Drug Administration on Thursday approved a new type of nonopioid painkiller from Vertex Pharmaceuticals, NBC ...

Many very preterm infants experience pain, according to a study published online Jan. 21 in Pain.Hillary Graham, fro ...

A new study led by researchers at University Hospitals Connor Whole Health found that adults with newly diagnosed sciatica who initially received chiropractic spinal manipulation (CSM) were ...